Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366957 | 0.90 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2284113 | 0.87 | TK1 (0.39) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL12373120 | 0.87 | TK1 (0.39) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13366937 | 0.84 | TK2 (0.36) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL14238797 | 0.82 | TERT (0.36) | TK1TK2 | |
| SCHEMBL12060321 | 0.82 | LMNA (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13082855 | 0.82 | LMNA (0.64) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2276807 | 0.81 | LMNA (0.34) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL8476367 | 0.81 | LMNA (0.38) | LMNASMN1; SMN2ALOX12ADRA1AALB | |
| SCHEMBL8476369 | 0.81 | LMNA (0.38) | LMNASMN1; SMN2ALOX12ADRA1AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-7771973-B2 | sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090325172-A1 | Modified nucleotides | SOLEXA LIMITED | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | RNMT, NSUN2, NSUN3 | LMNA 2798/4885SMN1; SMN2 1513/4885ALOX12 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.